Market Research Report
6 Reports Bundle: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin
|Published by||La Merie Publishing||Product code||651129|
Delivery time: 1-2 business days
|6 Reports Bundle: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin|
|Published: June 12, 2018||Content info:||
Intracellular cancer targets are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy. The six reports of this package are covering immunotherapeutics against six important intracellular cancer targets:
This report package includes six Competitor Analysis reports covering immunotherapeutics directed to six different important cancer targets. The original reports were published in May and June 2018, respectively:
Detailed report descriptions and tables of contents from the reports can be found on the respective product page. The reports can be acquired separately or as a package with a 40% discount on list prices.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.